Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Ciba-Geigy
gptkb:Searle_Pharmaceuticals |
| gptkbp:activities |
antagonist of serotonin and dopamine receptors
|
| gptkbp:approves |
gptkb:legislation
gptkb:1997 gptkb:United_States |
| gptkbp:associated_with |
metabolic syndrome
sedation cardiovascular risk orthostatic hypotension |
| gptkbp:brand |
gptkb:Seroquel_XR
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
severe liver impairment
hypersensitivity to quetiapine |
| gptkbp:developed_by |
gptkb:temple
|
| gptkbp:dosage_form |
400-800 mg per day
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
extended-release
immediate-release |
| https://www.w3.org/2000/01/rdf-schema#label |
Quetiapine
|
| gptkbp:ingredients |
C21 H25 N3 O2 S
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:is_atype_of |
N05 A H04
|
| gptkbp:is_available_in |
multiple countries
|
| gptkbp:is_available_on |
tablets
extended-release tablets |
| gptkbp:is_used_for |
treatment of schizophrenia
treatment of bipolar disorder treatment of major depressive disorder |
| gptkbp:lifespan |
6 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:Seroquel
|
| gptkbp:metabolism |
liver
|
| gptkbp:population |
gptkb:Person
adults adolescents |
| gptkbp:requires |
available online
|
| gptkbp:safety_features |
risk of seizures
risk of neuroleptic malignant syndrome risk of hyperglycemia risk of suicidal thoughts risk of tardive dyskinesia |
| gptkbp:side_effect |
dizziness
drowsiness constipation dry mouth weight gain |
| gptkbp:used_in |
off-label uses
|